<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567382</url>
  </required_header>
  <id_info>
    <org_study_id>17-2090</org_study_id>
    <secondary_id>IGHID 11720</secondary_id>
    <nct_id>NCT03567382</nct_id>
  </id_info>
  <brief_title>Arresting Vertical Transmission of Hepatitis B Virus</brief_title>
  <acronym>AVERT-HBV</acronym>
  <official_title>Arresting Vertical Transmission of Hepatitis B Virus in the Democratic Republic of the Congo: The AVERT-HBV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kinshasa School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to demonstrate the feasibility of adding HBV screening and&#xD;
      treatment of pregnant women to the existing HIV PMTCT platform in order to prevent&#xD;
      mother-to-child transmission of hepatitis B virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B virus (HBV) is a leading cause of chronic liver disease globally, with&#xD;
      devastating complications such as cirrhosis, hepatocellular carcinoma and death. Vertical&#xD;
      transmission (VT) of HBV is a worldwide public health concern because infected children are&#xD;
      at high risk of developing chronic liver disease. It is a particular problem in the&#xD;
      Democratic Republic of the Congo (DRC); preliminary data suggest that approximately 3% of&#xD;
      children have HBV infection due to VT. However, VT is preventable. Pregnant women with risk&#xD;
      factors can be identified and treatments given which can virtually eliminate transmission.&#xD;
      Unfortunately, despite the high burden of HBV, neither HBV testing of pregnant women nor&#xD;
      interventions to prevent HBV VT are routinely performed in the DRC and elsewhere in&#xD;
      sub-Saharan Africa. This pilot feasibility study will address this healthcare gap by&#xD;
      identifying women with HBV early in their pregnancies and intervening to prevent VT by (1)&#xD;
      treating mothers with high-risk HBV (defined as HBeAg positivity and/or HBV viremia &gt;10^6)&#xD;
      with tenofovir and (2) providing HBV vaccine to HBV-exposed infants within 24 hours of birth.&#xD;
      This pilot study will piggyback onto an existing study that is evaluating the DRC's HIV&#xD;
      Prevention of Maternal-to-Child Transmission Option B+ (PMTCT+) strategy. Combining programs&#xD;
      to prevent VT of HBV and HIV enables using the same personnel and infrastructure to implement&#xD;
      both interventions. Furthermore, tenofovir, used to treat HBV infections, is already used in&#xD;
      the DRC to treat HIV. Researchers hypothesize that utilizing the existing PMTCT+&#xD;
      infrastructure in the DRC will provide a cost-effective platform to prevent HBV VT. If&#xD;
      effective, this model of treatment will inform future public health efforts and wider policy&#xD;
      recommendations that can be applied in the DRC and throughout the Sub-Saharan African region&#xD;
      to reduce the burden of HBV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">August 15, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Lab Testing Acceptability Survey Scores &gt;80%</measure>
    <time_frame>Upon completion of the exit survey, or up to 12 months</time_frame>
    <description>The acceptability of laboratory testing approach to participants will be defined as &gt;80% acceptability on a two questions each measured using a 5-point Likert scale (range 1-5, highest score of 5 representing the highest acceptability). For example, the options for participant responses will include: &quot;Very unacceptable&quot; (1), &quot;Somewhat unacceptable&quot; (2), &quot;No opinion&quot; (3), &quot;Somewhat acceptable&quot; (4), &quot;Very acceptable&quot; (5) and &quot;Did not allow study personnel to take my blood&quot;. Scores equal to or greater than 4 considered 80%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Mothers With Infant Vaccination Acceptability Survey Scores &gt;80%</measure>
    <time_frame>Upon completion of the exit survey, or up to 12 months</time_frame>
    <description>The acceptability of the intervention approach to participants will be defined as &gt;80% acceptability on a single question measured using a 5-point Likert scale (range 1-5, highest score of 5 representing the highest acceptability). For example, the options for responses will include: &quot;Very unacceptable&quot; (1), &quot;Somewhat unacceptable&quot; (2), &quot;No opinion&quot; (3), &quot;Somewhat acceptable&quot; (4), &quot;Very acceptable&quot; (5) and &quot;Did not allow study personnel to vaccinate my infant&quot;. Scores equal to or greater than 4 considered 80%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With HBV Positivity at 6 Months of Life to Indicate Mother-to-Child Transmission of HBV</measure>
    <time_frame>Measured at 6 months after birth</time_frame>
    <description>Mother-to-child transmission of HBV is defined as HBsAg positivity in the infant at 6 months of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mothers With High-risk HBV Demonstrating Adherence to Tenofovir Therapy</measure>
    <time_frame>Pill counts to be measured monthly. Total adherence averaged over 6-month treatment period.</time_frame>
    <description>Adherence to tenofovir therapy is defined as &lt;20% of pills remaining on monthly pill counts for high-risk mothers with HBV receiving tenofovir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants Receiving Timely Birth Dose Vaccination</measure>
    <time_frame>Within 24 hours after birth</time_frame>
    <description>Timeliness of infant HBV vaccination is defined as &gt;90% of infants receiving birth dose vaccine within 24 hours of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Vertical Transmission of Infectious Disease</condition>
  <arm_group>
    <arm_group_label>High-risk HBV dyads</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mothers with high-risk HBV (defined as viral load &gt;10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-risk HBV dyads</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mothers with low risk HBV (defined as a viral load &lt;10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.</description>
    <arm_group_label>High-risk HBV dyads</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent HBV vaccine</intervention_name>
    <description>Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
    <arm_group_label>High-risk HBV dyads</arm_group_label>
    <arm_group_label>Low-risk HBV dyads</arm_group_label>
    <other_name>Engerix-B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Pregnant women receiving care at Binza and Kingasani maternity centers presenting&#xD;
             prior to 24 weeks gestation&#xD;
&#xD;
          -  Infants born to HBV-positive women&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Participants who are severely sick and who require prolonged hospitalization.&#xD;
&#xD;
          -  Any women who do not intend to stay in Kinshasa for prenatal care through delivery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Meshnick, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peyton Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kinshasa School of Public Health</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <results_first_submitted>January 14, 2021</results_first_submitted>
  <results_first_submitted_qc>January 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2021</results_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03567382/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-risk Mothers</title>
          <description>Mothers with high-risk HBV (defined as viral load &gt;10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.&#xD;
Tenofovir Disoproxil Fumarate: 300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
        </group>
        <group group_id="P2">
          <title>Low-risk Mothers</title>
          <description>Mothers with low risk HBV (defined as a viral load &lt;10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
        </group>
        <group group_id="P3">
          <title>Infants Born to High-risk Mothers</title>
          <description>Infants born to mothers with high-risk HBV</description>
        </group>
        <group group_id="P4">
          <title>Infants Born to Low-risk Mothers</title>
          <description>Infants born to mothers with low-risk HBV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Tenofovir</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data were not collected for the Infant Arm/Groups.</population>
      <group_list>
        <group group_id="B1">
          <title>High-risk Mothers</title>
          <description>Mothers with high-risk HBV (defined as viral load &gt;10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.&#xD;
Tenofovir Disoproxil Fumarate: 300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
        </group>
        <group group_id="B2">
          <title>Low-risk Mothers</title>
          <description>Mothers with low risk HBV (defined as a viral load &lt;10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.4" spread="5.4"/>
                    <measurement group_id="B2" value="30.59" spread="5.47"/>
                    <measurement group_id="B3" value="29.91" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Congo, The Democratic Republic of the</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at enrollment, Continuous</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="3.55"/>
                    <measurement group_id="B2" value="17.54" spread="4.65"/>
                    <measurement group_id="B3" value="17.91" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total pregnancies, Continuous</title>
          <units>pregnancies</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="2.06"/>
                    <measurement group_id="B2" value="3.52" spread="2.01"/>
                    <measurement group_id="B3" value="3.43" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of living children, Continuous</title>
          <units>living children</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.89" spread="1.54"/>
                    <measurement group_id="B2" value="2.25" spread="1.80"/>
                    <measurement group_id="B3" value="2.10" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status, Categorical</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Divorced</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Separated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Never Married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Highest Education, Categorical</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Primary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Secondary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Higher education</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Lab Testing Acceptability Survey Scores &gt;80%</title>
        <description>The acceptability of laboratory testing approach to participants will be defined as &gt;80% acceptability on a two questions each measured using a 5-point Likert scale (range 1-5, highest score of 5 representing the highest acceptability). For example, the options for participant responses will include: &quot;Very unacceptable&quot; (1), &quot;Somewhat unacceptable&quot; (2), &quot;No opinion&quot; (3), &quot;Somewhat acceptable&quot; (4), &quot;Very acceptable&quot; (5) and &quot;Did not allow study personnel to take my blood&quot;. Scores equal to or greater than 4 considered 80%.</description>
        <time_frame>Upon completion of the exit survey, or up to 12 months</time_frame>
        <population>There were a total of 53 mothers (7 high-risk and good 46 low-risk) who completed the 6-month study visit, thus this is the total number of mothers who completed the exit survey. One survey was completed per mother/infant dyad.</population>
        <group_list>
          <group group_id="O1">
            <title>High-risk Mothers</title>
            <description>Mothers with high-risk HBV (defined as viral load &gt;10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.&#xD;
Tenofovir Disoproxil Fumarate: 300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
          </group>
          <group group_id="O2">
            <title>Low-risk Mothers</title>
            <description>Mothers with low risk HBV (defined as a viral load &lt;10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Lab Testing Acceptability Survey Scores &gt;80%</title>
          <description>The acceptability of laboratory testing approach to participants will be defined as &gt;80% acceptability on a two questions each measured using a 5-point Likert scale (range 1-5, highest score of 5 representing the highest acceptability). For example, the options for participant responses will include: &quot;Very unacceptable&quot; (1), &quot;Somewhat unacceptable&quot; (2), &quot;No opinion&quot; (3), &quot;Somewhat acceptable&quot; (4), &quot;Very acceptable&quot; (5) and &quot;Did not allow study personnel to take my blood&quot;. Scores equal to or greater than 4 considered 80%.</description>
          <population>There were a total of 53 mothers (7 high-risk and good 46 low-risk) who completed the 6-month study visit, thus this is the total number of mothers who completed the exit survey. One survey was completed per mother/infant dyad.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testing for Mothers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testing for Infants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Mothers With Infant Vaccination Acceptability Survey Scores &gt;80%</title>
        <description>The acceptability of the intervention approach to participants will be defined as &gt;80% acceptability on a single question measured using a 5-point Likert scale (range 1-5, highest score of 5 representing the highest acceptability). For example, the options for responses will include: &quot;Very unacceptable&quot; (1), &quot;Somewhat unacceptable&quot; (2), &quot;No opinion&quot; (3), &quot;Somewhat acceptable&quot; (4), &quot;Very acceptable&quot; (5) and &quot;Did not allow study personnel to vaccinate my infant&quot;. Scores equal to or greater than 4 considered 80%.</description>
        <time_frame>Upon completion of the exit survey, or up to 12 months</time_frame>
        <population>There were a total of 53 mothers (7 high-risk and 46 low-risk) who completed the 6-month study visit, thus this is the total number of mothers who completed the exit survey. One survey was completed per mother/infant dyad.</population>
        <group_list>
          <group group_id="O1">
            <title>High-risk Mothers</title>
            <description>Mothers with high-risk HBV (defined as viral load &gt;10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.&#xD;
Tenofovir Disoproxil Fumarate: 300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
          </group>
          <group group_id="O2">
            <title>Low-risk Mothers</title>
            <description>Mothers with low risk HBV (defined as a viral load &lt;10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mothers With Infant Vaccination Acceptability Survey Scores &gt;80%</title>
          <description>The acceptability of the intervention approach to participants will be defined as &gt;80% acceptability on a single question measured using a 5-point Likert scale (range 1-5, highest score of 5 representing the highest acceptability). For example, the options for responses will include: &quot;Very unacceptable&quot; (1), &quot;Somewhat unacceptable&quot; (2), &quot;No opinion&quot; (3), &quot;Somewhat acceptable&quot; (4), &quot;Very acceptable&quot; (5) and &quot;Did not allow study personnel to vaccinate my infant&quot;. Scores equal to or greater than 4 considered 80%.</description>
          <population>There were a total of 53 mothers (7 high-risk and 46 low-risk) who completed the 6-month study visit, thus this is the total number of mothers who completed the exit survey. One survey was completed per mother/infant dyad.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With HBV Positivity at 6 Months of Life to Indicate Mother-to-Child Transmission of HBV</title>
        <description>Mother-to-child transmission of HBV is defined as HBsAg positivity in the infant at 6 months of life.</description>
        <time_frame>Measured at 6 months after birth</time_frame>
        <population>A total of 88 infants were born to mothers in the study, but only 53 infants (7 born to high-risk mothers and 46 born to low-risk mothers) were followed through 6 months of life and tested for HBsAg at that time.</population>
        <group_list>
          <group group_id="O1">
            <title>Infants Born to High-risk Mothers</title>
            <description>Infants born to mothers with high-risk HBV</description>
          </group>
          <group group_id="O2">
            <title>Infants Born to Low-risk Mothers</title>
            <description>Infants born to mothers with low-risk HBV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With HBV Positivity at 6 Months of Life to Indicate Mother-to-Child Transmission of HBV</title>
          <description>Mother-to-child transmission of HBV is defined as HBsAg positivity in the infant at 6 months of life.</description>
          <population>A total of 88 infants were born to mothers in the study, but only 53 infants (7 born to high-risk mothers and 46 born to low-risk mothers) were followed through 6 months of life and tested for HBsAg at that time.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Mothers With High-risk HBV Demonstrating Adherence to Tenofovir Therapy</title>
        <description>Adherence to tenofovir therapy is defined as &lt;20% of pills remaining on monthly pill counts for high-risk mothers with HBV receiving tenofovir</description>
        <time_frame>Pill counts to be measured monthly. Total adherence averaged over 6-month treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-risk Mothers</title>
            <description>Mothers with high-risk HBV who took tenofovir during pregnancy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mothers With High-risk HBV Demonstrating Adherence to Tenofovir Therapy</title>
          <description>Adherence to tenofovir therapy is defined as &lt;20% of pills remaining on monthly pill counts for high-risk mothers with HBV receiving tenofovir</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants Receiving Timely Birth Dose Vaccination</title>
        <description>Timeliness of infant HBV vaccination is defined as &gt;90% of infants receiving birth dose vaccine within 24 hours of life</description>
        <time_frame>Within 24 hours after birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infants Born to High-risk Mothers</title>
            <description>Infants born to mothers with high-risk HBV</description>
          </group>
          <group group_id="O2">
            <title>Infants Born to Low-risk Mothers</title>
            <description>Infants born to mothers with low-risk HBV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants Receiving Timely Birth Dose Vaccination</title>
          <description>Timeliness of infant HBV vaccination is defined as &gt;90% of infants receiving birth dose vaccine within 24 hours of life</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The participants were monitored for adverse events over the duration of treatment (an average of 6 months for High-risk Mothers taking tenofovir therapy, and an average of 3 days or the duration of hospital stay for infants after receiving hepatitis B vaccination). Since Low-risk Mothers did not receive a study intervention, adverse event data was not overtly sought unless self-reported by participant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High-risk Mothers</title>
          <description>Mothers with high-risk HBV (defined as viral load &gt;10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.&#xD;
Tenofovir Disoproxil Fumarate: 300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
        </group>
        <group group_id="E2">
          <title>Low-risk Mothers</title>
          <description>Mothers with low risk HBV (defined as a viral load &lt;10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.&#xD;
Monovalent HBV vaccine: Infants born to HBsAg-positive mothers will be given a single dose of monovalent HBV vaccine within 24 hours of life.</description>
        </group>
        <group group_id="E3">
          <title>Infants Born to High-risk Mothers</title>
          <description>Infants born to mothers with high-risk HBV</description>
        </group>
        <group group_id="E4">
          <title>Infants Born to Low-risk Mothers</title>
          <description>Infants born to mothers with low-risk HBV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Rebound elevation of ALT and HBV DNA after discontinuation of Tenofovir</sub_title>
                <description>ALT = alanine aminotransferase DNA = deoxyribonucleic acid</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peyton Thompson, MD, MSCR</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-445-0854</phone>
      <email>peyton_thompson@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

